Um, that dude is the world's biggest pumper. You should read the articles he did on ZLCS. That one worked out well.
Um, powerful resources that have been through the rigmarole of getting a drug to market as quickly as possible and have the werewithal and contacts to make it happen in a more timely manner? This management team clearly hasn't been up to the task thus far.
Bull. You don't have to partner the entire pipeline. Plenty of companies partner for single drugs, and many have several partners across their portfolio. It would have been at the company's discretion. They could have easily partnered eteplirsen alone, while keeping the rest of the pipeline to themselves.
"How can things be worse?"
Exactly. That's a pretty good reason to add, isn't it? You know, buy at the lows, sell at the highs. That being said, biotech looks like it might want to match or best April lows, so buying any biotech right now is a huge risk.
The United States does not allow unapproved drugs to be shipped and used overseas. So unless someone raises a stink, people in Africa are unfortunately screwed.
Don't know about MGNX, gary. Looking in clinicaltrials.gov, it appears a few of their drugs are serious flops.
Gotcha. I personally like CMRX. It has a very similar story to eteplirsen. Anecdotal evidence, but their lead drug clearly works. And they are presenting next week. Could have an update about Josh Hardy.
You clearly don't know what evidence means. As noted in AF's article, Art isn't the only person to have left in recent times. Additionally, the constant talk of Chris butting heads with the FDA is likely true, given all that has happened with that situation. Last but not least, why haven't we partnered on anything? Wanting to go it alone when you clearly aren't up to the task would count as arrogance, in my opinion. I've been one to give Chris the benefit of the doubt for a long time, but between all of these things, the excessive options grants, and the fact that he has not once made an open market purchase of shares, it's hard to continue putting faith in him.
I cut my position to peanuts (compared to what I previously owned) shortly after the FDA turn of events. The history of this stock pretty much guaranteed a big drop. So I don't have much reason to whine about the share price. I'd be more likely to whine if it did triple since I only own 25% of the shares that I used to own, and I'd miss out.
Wilton is a scientist, first and foremost. You are making a huge assumption that he has a lot of business acumen, which is something we have no way of knowing. What starfe said. It's a bad idea. I'm sure rather than debate the point, you'll simply say we're the same person as if that makes for a logical argument.
Not likely. Wilton is a lab rat. Unlikely he'd want to go corporate (as that would take him away from the work he currently does), let alone move halfway across the world. I'd rather he stay in the lab and keep creating value for the company that way.
Micro, I definitely agree that even if a boy loses ambulation, it does not change the endgame with the FDA. The drug still works. But I think it's a bit starry-eyed to think the stock won't get destroyed by shorts if this happens.
Because three of them have declined significantly. Of those three, I believe at least two of them are now below 300 meters on the 6MWT. That is precariously close to the point where most boys end up in wheelchairs. If they had significant declines from 120 weeks to 144 weeks, it's a fair bet that the same will happen between 144 weeks to 168 weeks. And given how far they walked at 144 weeks, it is again a fair bet that at least one will be in a wheelchair by 168 weeks. I think all of us hope this does not occur, and not because of what would happen to the stock price. DMD is a horrible disease and no boy should have to suffer from it.
So you wouldn't take a buyout tomorrow at $75/share? I would. (I would scoff at any buyout below $70/share.) The risks here are considerable, no matter how you slice it. $75/share today could easily be turned into a profit equivalent $150/share by the end of 2015, and I think it's fair to say SRPT won't be $150 by the end of 2015, even with an approval.
I would also be completely fine with a partnership. If the terms are good, that would be better than a buyout.
People need to wake up to the reality that there is a very good chance that at least one boy will be non-ambulatory by 168 weeks. You think shorts aren't going to destroy the stock if that happens? This latest drop will look weak by comparison.